These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 20180626)

  • 21. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
    Willeke F; Horisberger K; Kraus-Tiefenbacher U; Wenz F; Leitner A; Hochhaus A; Grobholz R; Willer A; Kähler G; Post S; Hofheinz RD
    Br J Cancer; 2007 Mar; 96(6):912-7. PubMed ID: 17325705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
    Koeberle D; Burkhard R; von Moos R; Winterhalder R; Hess V; Heitzmann F; Ruhstaller T; Terraciano L; Neuweiler J; Bieri G; Rust C; Toepfer M
    Br J Cancer; 2008 Apr; 98(7):1204-9. PubMed ID: 18349837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
    Gao YH; Lin JZ; An X; Luo JL; Cai MY; Cai PQ; Kong LH; Liu GC; Tang JH; Chen G; Pan ZZ; Ding PR
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1153-60. PubMed ID: 25442042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
    Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Cassidy J; Hochster H
    Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
    Czito BG; Willett CG; Bendell JC; Morse MA; Tyler DS; Fernando NH; Mantyh CR; Blobe GC; Honeycutt W; Yu D; Clary BM; Pappas TN; Ludwig KA; Hurwitz HI
    J Clin Oncol; 2006 Feb; 24(4):656-62. PubMed ID: 16446337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
    Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
    Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
    ; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
    J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
    Stintzing S; Kapaun C; Laubender RP; Jung A; Neumann J; Modest DP; Giessen C; Moosmann N; Wollenberg A; Kirchner T; Heinemann V
    Int J Cancer; 2013 Jan; 132(1):236-45. PubMed ID: 22644776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Landherr L; Nagykálnai T
    Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
    Heudel P; Romestaing P; Barbet N; Falandry C; You B; Glehen O; Freyer G
    Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):369-74. PubMed ID: 18406583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
    Sclafani F; Roy A; Cunningham D; Wotherspoon A; Peckitt C; Gonzalez de Castro D; Tabernero J; Glimelius B; Cervantes A; Eltahir Z; Oates J; Chau I
    Ann Oncol; 2013 Dec; 24(12):3123-8. PubMed ID: 24146218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.
    Hospers GA; Punt CJ; Tesselaar ME; Cats A; Havenga K; Leer JW; Marijnen CA; Jansen EP; Van Krieken HH; Wiggers T; Van de Velde CJ; Mulder NH
    Ann Surg Oncol; 2007 Oct; 14(10):2773-9. PubMed ID: 17653805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined cetuximab, capecitabine, oxaliplatin, and radiotherapy in rectal cancer: Dr. Jekyll or Mr. Hyde? In regard to Rödel et al. (Int J Radiat Oncol Biol Phys 2008;70:1081-1086.).
    Azria D
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):959-60; author reply 960. PubMed ID: 18514789
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).
    Pinto C; Di Fabio F; Maiello E; Pini S; Latiano T; Aschele C; Garufi C; Bochicchio A; Rosati G; Aprile G; Giaquinta S; Torri V; Bardelli A; Gion M; Martoni A
    Ann Oncol; 2011 Nov; 22(11):2424-2430. PubMed ID: 21385884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
    Bertolini F; Chiara S; Bengala C; Antognoni P; Dealis C; Zironi S; Malavasi N; Scolaro T; Depenni R; Jovic G; Sonaglio C; Rossi A; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):466-72. PubMed ID: 19004567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A resected case of locally invasive rectal cancer successfully treated with neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy].
    Suzuki S; Shigaki N; Yokoyama S; Yamashita H; Sugita H; Arima N
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1545-7. PubMed ID: 21918360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.